Skip to main content

ViraCor, IBT to Merge

NEW YORK (GenomeWeb News) – ViraCor Laboratories and IBT Laboratories announced today that they will merge to form a new specialty diagnostic testing lab.

The merger will combine ViraCor's molecular diagnostic testing services with IBT's focus on immunology and allergy testing. Terms of the merger were not disclosed.

"This merger gives ViraCor and IBT the combined scientific know-how and national network not only to reach additional customers who could benefit from our current test menu, but also to expand our services, providing the critical diagnostic information that clinicians need to improve health outcomes for patients," ViraCor President John Martin, who will serve as president of the combined company, said in a statement.

The merged entity will employ more than 200 staffers and will serve more than 4,000 physicians, hospitals, commercial labs, and biopharmaceutical companies, the firms said.

The firm also expects to continue operating out of its two labs, which are located only 22 miles apart in the Kansas City area.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.